|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of goods sold | |||||
| Gross profit | |||||
| Selling, general and administrative expenses | |||||
| Goodwill impairment | |||||
| Long-lived asset impairment charges | |||||
| Restructuring charges and asset write-offs | |||||
| Research and development expenses | |||||
| Gain on change in interest in properties/sale of business, net | |||||
| Operating (loss) profit | |||||
| Interest and financing expenses | |||||
| Other income, net | |||||
| (Loss) income before income taxes and equity in net income of unconsolidated investments | |||||
| Income tax expense | |||||
| Loss before equity in net income of unconsolidated investments | |||||
| Equity in net income of unconsolidated investments (net of tax) | |||||
| Net (loss) income | |||||
| Net income attributable to noncontrolling interests | |||||
| Net (loss) income attributable to Albemarle Corporation | |||||
| Mandatory convertible preferred stock dividends | |||||
| Net (loss) income attributable to Albemarle Corporation common shareholders, basic | |||||
| Net (loss) income attributable to Albemarle Corporation common shareholders, diluted | |||||
| Basic earnings (loss) per share attributable to common shareholders (in dollars per share) | |||||
| Diluted earnings (loss) per share attributable to common shareholders (in dollars per share) | |||||
| Weighted-average common shares outstanding—basic (in shares) | |||||
| Weighted-average common shares outstanding—diluted (in shares) |
Loading...